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Abstract 
Background: Sarcoidosis is a multisystem granulomatous disorder of 
unknown etiology, characterized by “noncaseating granulomas” in 
different organs. Clinical signs are variable and dependent on the 
organ involved. Although it is often asymptomatic in athletes, 
considering the high level of athletic performance and the related risks 
due to the potential heart involvement, a particular diagnostic flow-
chart to consider some other diagnoses is required. The present case 
report aimed to focus on the clinical approach in case of a progressive 
weakness associated with a reduction in global performance of an 
athlete. 
Case Presentation: Since October 2008 a 33-year-old Scandinavian 
professional soccer player has shown splitting headache, fever and 
impaired exercise tolerance. Despite some clinical aspects and 
symptoms that could address diagnosis of granulomatosis according to 
the current guidelines, the first hypothesis was indicative of a possible 
viral infection. Therefore, the athlete had received a drug-therapy 
resolving the headache and fever. However, because of the persisting 
weakness, several other clinical possibilities were evaluated following a 
more complete diagnostic flow-chart, blood and instrumental exams. 
Conclusion: This case report focuses on the substantial absence of 
symptoms during the granulomatosis disease, which makes the 
differential diagnosis to be often complicating. Indeed, several 
additional exams are required in order to establish the presence of 
“Non-evolutive sarcoidosis- stage I”, for which the therapy is not 
mandatory.  
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INTRODUCTION 
Sarcoidosis is a multisystem disease with unknown 
etiology, characterized by the presence of 
“noncaseating granulomas” in several organs. Despite 
the fact that exact prevalence of sarcoidosis is not 
known yet, its incidence in people like black 
Americans and Scandinavians is higher than 
others
[1,2,3]. The greatest incidence has been observed in 
young adults aged between 20 and 40 years. Athletes  
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can also be involved with an evident reduction in their 
sport performance. For almost 50% of the patients the 
diagnosis is often casual or occasional in case of the 
evident pulmonary radiographic abnormalities. 
Actually, the accurate etiology of the disease is not 
exactly known. It has been supposed to be mainly 
found in susceptible subjects as a consequence of an 
inflammatory response of organism to external inputs. 
The possible causes of immunologic response could be 
infections (viral, bacterial or mycobacterial) or 
inhalation of organic and inorganic agents. The 
inflammatory response is therefore characterized by 
accumulation of T-lymphocytes and macrophages with 
consequent organization of granulomas
[4]. According to 
the current guidelines
[4], diagnosis of Sarcoidosis is 
actually based on the presence of typical symptoms 
(fever, fatigue, malaise, asthenia, dyspnea, cough, 
polyarthralgia, lymphadenopathy), high plasma level of 
a peculiar enzyme i.e. Angiotensin Converting Enzyme 
(ACE), presence of a bilateral hilar lymphadenopathy 
at the standard chest radiological exam and histological 
evidence of noncaseating epithelioid cell granulomas
[4]. 
In order to confirm the diagnosis, some additional 
laboratory and instrumental exams (Purified Protein 
Derivative (PPD) skin test; serum level of erythrocyte 
sedimentation rate (ESR), C-reactive protein (PCR), 
Calcium, Phosphate; Kveim reaction test; complete 
microbiologic tests, Holter monitoring, 
echocardiography and thallium or gallium scans, 
magnetic resonance imaging (MRI), CT scans of the 
central nervous system and myocardial involvement 
can be helpful
[4]. In spite of the fact that the most 
typical symptoms of sarcoidosis include cough, 
dyspnea, thoracic pain, fever and the weakness, a 
substantial absence of symptoms can be found in 90% 
of the patients, where bilateral hilar adenopathy and 
interstitial or alveolar opacities are often evident. Just 
in cases with big conglomerate clusters of granulomas, 
especially in the upper parts of lungs, due to the 
presence of the stenosis or bronchiectasis, the 
symptoms can be found
[5]. Otherwise, involvement of 
different organs and tissues in athletes is frequent: in 
10% of them the skeletal-muscles show acute 
polyarthritis, especially in hips. Besides, tendons and 
peritendinous tissue can be affected by a degenerative 
process that can result in breakage, especially in cases 
of protracted stress. The cardiac injury occurs more 
frequently in Japanese female population 
(approximately 20-47% of patients). This aspect 
determines 85% of deaths from sarcoidosis. However, 
the symptoms are observed only in 5% of cases and the 
survival up to five years is evident in about 60% of the 
subjects
[6]. A cardiac sarcoidosis characterized by wide 
fibrotic areas, can involve the pericardium, the 
endocardium, or the myocardium areas, mainly in the 
free wall of the left ventricle and in the interventricular 
septum creating some possible arrhythmias (from a 
first grade atrioventricular block to a complete block, 
atrial arrhythmias, sustained or non-sustained 
ventricular tachycardia) due to a reentry loop
[7]. A 
potential evolution toward the left ventricle dilatation 
with heart failure has also been described (8,9,10). 
Diagnosis of cardiac sarcoidosis is possible by the 
electrocardiographic, echocardiographic and radio-
nuclide investigations (Gadolinium MRI exam), while 
the gallium-67 citrate (Ga) or Thallium-201 
scintigraphy are normally used to assess the activity of 
the disease and the response to the corticosteroid 
therapy
[11-13].  Cardiac biopsy is normally avoided 
because of the high level of risk associated with a low 
sensitivity
[14]. In conclusion, the chest XR is generally 
the first exam to support the diagnosis of sarcoidosis. 
However, in case of doubt, a chest CT in addition to 
the bioptic sampling can be helpful to identify the 
granulomas and also to perform the differential 
diagnosis among other “granulomatous diseases”. The 
respiratory functional tests remain however the main 
tests to estimate the disease’s severity, showing normal 
values at the first stages and a restriction pattern with a 
reduced diffusion of CO in advanced stages
[15]. 
CASE PRESENTATION 
The patient gave oral consent to participate in this case 
report. Since October 2008 a 33-years-old 
Scandinavian professional soccer player has shown 
splitting headache with fever and meningitic irritation 
signs like photophobia.  
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      The  first  diagnostic  hypothesis  was  addressed 
toward a Toscana Virus infection that occurs frequently 
in this area. Initially, all serologic tests were negative. 
Head CT scans and magnetic resonance angiography 
(MRA) were negative either. Only a slight increase of 
ACE and unspecific flogosis-indexes like ESR and 
CRP were evident. Despite these results, he was 
submitted to a corticosteroid therapy with the 
resolution of the headache and fever. However, 
considering the persisting strong weakness with an 
inevitable negative impact on his sport performance, 
some other possible causes for the asthenia were 
considered and evaluated following an additional 
diagnostic flow-chart. The examinations made during 
one more month spent in the hospital showed normal 
values of the general blood tests, no serological signs 
of lymphoma along with a little increase of ACE 
plasma level. The serologic tests by polymerase chain 
reaction technique (PCR) including PPD skin test 
resulted to be negative except a past Toscana Virus 
(IgG) infection.  
     Among  the  cardiological  investigations,  the 
echocardiographic exam was normal while Maximal 
Ergometric Test (MET) showed sporadic singular 
monomorphic ventricular extrasystoles. In addition, 24-
hour Holter-monitoring ECG showed some 
polymorphic ventricular extrasystoles, partially 
organized in short bigeminal rhythm, and 
monomorphic and polymorphic couples at rest 
condition. 
     The respiratory functional tests described a pattern 
compatible with a slight obstruction and a normal CO 
diffusion. The chest XR was characterized by a 
moderate parenchymal involvement due to a hilar 
lymphadenopathy (Fig. 1). The abdominal echography 
showed an enhancement of the liver and spleen 
dimensions at the presence of abdominal lymph nodes, 
presence of which was confirmed by the abdominal 
and chest CT (Fig. 2). Increase of inguinal, 
mediastinal, supraclavicular and cervical lymph nodes 
with the same pattern were also described (Fig. 3). The 
additional evaluation by Positron Emission 
Tomography (PET/CT) showed a mediastinal and 
supraclavicular areas with higher glucose-metabolism 
than others.  In the meantime, the athlete was quite 
asymptomatic and the weakness was the sign more 
constant. Therefore, diagnosis of sarcoidosis was 
supposed. The athlete was submitted to a bioptic
   
Fig. 1: The pictures of the chest by X-ray exam in two different visualizations show the pulmonary involvement due to a 
hilar lymphadenopathy  
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Fig. 2: The CT image shows the presence of inguinal lymph nodes 
 
sampling of the laterocervical lymph nodes confirming 
the diagnosis previously hypothesized. Biopsy showed 
“noncaseating granulomas”.  
     Considering the quite good clinical condition of the 
athlete, no more additional pharmacologic therapy 
except one month of detraining was advised. He was in 
a fairly good physical state thirty days later, and the 
follow-up exams didn’t show any more progression of 
the disease. He gradually restarted his training after 
four months and he actually was in good performance.  
 
 
Fig. 3: The CT image shows the increase of mediastinal lymph nodes  
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DISCUSSION 
The symptom “asthenia” in a professional athlete is 
often described as loss of his global performance. In 
case of “unspecific symptoms” like headache, muscular 
fatigue and fever, it is necessary to reduce the time of 
sportive seasonal training to avoid the negative 
consequences of the overtraining. When it is possible 
to exclude any relation between symptoms and sport 
activity, it is correct to suspect a common pathology as 
flu syndrome or infective pathologies. Otherwise, 
according to previous examples of cases reported
[22,23], 
where exclusively unspecific clinical symptoms are 
evident and the most common pathologies can be 
excluded, some other diseases as lymphoma, 
tuberculosis, rheumatoid arthritis, rheumatic fever and 
mycosis have to be considered. Besides, when these 
ones can be excluded, it is consequently reasonable to 
think of sarcoidosis. Fatigue is the most common and 
the major problem in young patients with sarcoidosis, 
submitted or not submitted to a corticosteroid therapy. 
As no direct relation is often evident between fatigue 
and clinical parameters, it is very difficult to evaluate 
this aspect. No standard quantification of these 
symptoms has been determined yet. The Fatigue 
Assessment Scale (FAS), and the 6-minute walk
[15-17] 
can be considered now as the exclusive valid 
instruments to assess this one and are able to show the 
impaired exercise tolerance due to multiple factors 
above
[18-20]. Sarcoidosis can often involve unexpected 
organs
[22,23] and only the evidence of noncaseating 
granulomas can confirm the doubt.  
 Correct diagnosis of sarcoidosis is therefore possible 
following a flow-chart to obtain a complete differential 
diagnosis panel, considering the presence of symptoms, 
the radiologic signs, in addition to a histopathologic 
confirmation.  After the anamnesis and the physical 
examination several other exams are necessary:  
-  Complete blood tests 
-  ECG, echocardiogram, ECG sec. Holter 
-  Respiratory functional tests 
-  Chest XR  
-  Chest CT: especially in advanced stages of 
disease, when the radiologic images can 
simulate pulmonary metastasis 
-  MRI or scintigraphy with Gallium-67 or 
Tallium-201 
-  Transbronchial bronchoscopy and biopsy 
 
Ninety percent of patients have a spontaneous 
resolution after two years, while restarting the disease 
is evident in less than 10% of them. On the contrary, 
sarcoidosis becomes chronic with permanent issues in 
30% of the cases. The symptomatic subjects are 
normally submitted to a corticosteroid therapy 
(Prednisone 0.3-1 mg/Kg/day until a maximum of 40 
mg/day). If the patient shows a good resolution of the 
disease within the first two weeks of therapy, he can be 
considered a “responder”. When the corticosteroid 
therapy is interrupted, restart of the disease activity is 
possible. 
          In cases of side-effects or if the athlete is “non-
responder”, an alternative therapy can be tried with 
azathioprine, cyclophosphamide, chlorambucil, 
chloroquine, pentoxifylline or infliximab
[21,14]. The rate 
of the follow-up depends on stage and degree of the 
disease: every 4-8 weeks in subjects with acute 
sarcoidosis and corticosteroid therapy can be sufficient, 
whereas a 3-4-month period is acceptable in the first 
years and more rarely afterwards if the disease is 
indolent
[21].
 
CONCLUSION 
The data obtained show a “sarcoidosis on first stage”, 
which has not been developed yet and is exclusively 
characterized by clinical manifestations, i.e. the 
persistent asthenia. 
          This case report supports the assumption that 
therapy is not normally necessary in asymptomatic 
subjects. Respiratory functional tests and blood 
markers of disease are often sufficient, especially when 
the symptoms are restricted to a weakness. A different 
period of detraining is, in fact, sufficient to restitute the 
performance previously lost.  
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